Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
Stock news
By buying an index fund, investors can approximate the average market return. But if you buy good businesses at...
Independently reviewed safety run-in data prompts recommendation to initiate enrolment for the randomised portion of the Phase II EAT COVID studyUp to 110 COVID-19 patients to participate in investigator-initiated study at the University Hospital Pilsen, Czech Republic Sydney, AUSTRALIA , Jan. 27, 2021 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune disease, anno...
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Jan. 26) Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) Aslan Pharmaceuticals Ltd (NASDAQ: ASLN) (reacted to new preclinical data showing its investigational asset ASLAN003 have the lowest potential for hepatotoxicity) BIOLASE Inc (NASDAQ: BIOL) (reacted to its preliminary fourth-quarter results) BioNano Genomics Inc ...
Here's a roundup of top developments in the biotech space over the last 24 hours.Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Jan. 21) * Acasti Pharma Inc (NASDAQ: ACST) * Alimera Sciences Inc(NASDAQ: ALIM) * argenx SE - ADR (NASDAQ: ARGX) * Axonics Modulation Technologies Inc (NASDAQ: AXNX) * AzurRx BioPharma Inc (NASDAQ: AZRX) * Chimerix Inc (NASDAQ: CMRX) * Edap Tms SA(NASDAQ: EDAP) * Eli Lilly And Co (NYSE: LLY) (announced positive results for its COVID-19 antibody treatme...
Highlights Encouraging efti data reported from phase IIb AIPAC and phase II TACTI-002 clinical trialsTACTI-002 study expanded in lung cancerNew phase II trial in head and neck cancer announcedEOC Pharma starts new phase II study in metastatic breast cancerRobust operational and financial position, with $54.9 million in cash as at 31 December 2020, providing cash runway beyond the end of calendar year 2022 Sydney, AUSTRALIA, Jan. 22, 2021 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMM...
Immutep’s Collaboration and Exclusive License with GSK Remains in PlaceSydney, AUSTRALIA, Jan. 22, 2021 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune disease, advises that one of its licensing partners, GSK, has discontinued its Phase II clinical trial evaluating an anti-LAG3 cell depleting monoclonal antibody, GSK2831781 (derived from Immutep’s IMP731 antibody...
Here's a roundup of top developments in the biotech space over the last 24 hours:Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Jan. 6) * 9 Meters Biopharma Inc (NASDAQ: NMTR) * AngioDynamics, Inc. (NASDAQ: ANGO) * Atea Pharmaceuticals, Inc. (NASDAQ: AVIR) * AxoGen, Inc Common Stock (NASDAQ: AXGN) * Axonics Modulation Technologies Inc (NASDAQ: AXNX) * BIO-TECHNE Corp (NASDAQ: TECH) * Endo International PLC (NASDAQ: ENDP) * Eyenovia Inc (NASDAQ: EYEN) * Fulgent Genetics Inc (NAS...